No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATRA240719P500
- 0.13
- 0.000.00%
15min DelayClose Jun 17 13:34 ET
0.00High0.00Low
0.00Open0.13Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover0.00%IV96.64%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma84.69Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Cuts Target Price to $13
CCORF analyst John Newman maintains $Atara Biotherapeutics(ATRA.US)$ with a buy rating, and adjusts the target price from $500 to $13.According to TipRanks data, the analyst has a success rate of 39.6
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Lead Asset Tab-cel Undergoes FDA Priority Review
Atara Biotherapeutics Price Target Cut to $11.00/Share From $12.50 by Goldman Sachs
Atara Biotherapeutics Price Target Cut to $11.00/Share From $12.50 by Goldman
Atara Biotherapeutics Is Maintained at Sell by Goldman Sachs
Atara Biotherapeutics Is Maintained at Sell by Goldman
Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11
Goldman Sachs analyst Tommie Reerink maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Sell and lowers the price target from $12.5 to $11.
Comments
$Atara Biotherapeutics(ATRA.US$ Reuters· PDUFA for BLA is January 20th
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA
$Atara Biotherapeutics(ATRA.US$ Atara Biotherapeutics To Conduct 1-for-25 Reverse Stock Split, Effective Jun. 20
1
4
$Atara Biotherapeutics(ATRA.US$ Reuters· 7 mins ago
Atara Biotherapeutics - Preclinical Results Support Advancing ATA3219 Towards Clinical Evaluation in Patients With B-Cell Driven Autoimmune Diseases
Atara Biotherapeutics - Preclinical Results Support Advancing ATA3219 Towards Clinical Evaluation in Patients With B-Cell Driven Autoimmune Diseases
2
$Atara Biotherapeutics(ATRA.US$
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at th...
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at th...
1
$Atara Biotherapeutics(ATRA.US$
NEWS
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
05/20/2024 - 06:25 AM First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, ...
NEWS
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
05/20/2024 - 06:25 AM First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, ...
1
Read more